KVCT

RefleXion Showcases Breakthrough SCINTIX Biology-Guided Radiotherapy and Highlights New Research at ASTRO 2023 Meeting

Retrieved on: 
Thursday, September 28, 2023

RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).

Key Points: 
  • RefleXion® Medical , a therapeutic oncology company, today announced the company will showcase the RefleXion® X1 with SCINTIX™ biology-guided radiotherapy at the American Society for Radiation Oncology ( ASTRO ) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831).
  • “Highlights from these presentations explore critical aspects of X1 performance in dosimetric accuracy, workflow, FDG uptake, and exquisite kVCT image quality.
  • The following oral and panel presentations highlight some of the new research being presented at ASTRO 2023.
  • The RefleXion booth will also feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.

RefleXion Announces Real-World Evidence Outcomes Registry to Evaluate Treatment Impact on all Stages of Cancer

Retrieved on: 
Tuesday, May 3, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220503005487/en/
    The RefleXion X1 radiotherapy system is the first-ever system with onboard fast fan-beam KVCT.
  • The PREMIER registry was created to collect data to demonstrate the impact of the RefleXion X1 radiotherapy system, the first-ever system with onboard fast fan-beam KVCT, on patients with all solid tumor and lymphoma cancer types.
  • The registry will expand to include BgRT procedures, a new radiotherapy treatment modality that uses signals detected from positron emission tomography (PET) to guide radiotherapy.
  • The PREMIER registry will assess health-related quality of life, acute and long-term side effects in patients, and cancer-related outcomes.

Largest Hospital in Queensland, Australia Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies

Retrieved on: 
Monday, February 14, 2022

ClearRT, a helical CT imaging solution, was created to empower medical care teams to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively.

Key Points: 
  • ClearRT, a helical CT imaging solution, was created to empower medical care teams to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively.
  • Based on the team's experience with TomoTherapy, they considered Radixact to be the ideal system for them.
  • It offers continuous 360-degreeprecision plus much needed flexibility with the integration of ClearRT and Synchrony.
  • Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible.

Global Surgery and Radiation Therapy in Brain Cancer Market Insight, Competitive Landscape and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021

The epidemiology division's Surgery and Radiotherapy in Brain Cancer symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries.

Key Points: 
  • The epidemiology division's Surgery and Radiotherapy in Brain Cancer symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries.
  • It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
  • The total 7MM prevalent cases of Surgery and Radiotherapy in Brain Cancer were 60,103 in 2020.
  • There have been various developments and collaborations in the field of Surgery and Radiation Therapy in Brain Cancer.

French Hospital Network Unicancer Acquires Multiple Accuray Radixact® Systems with the ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony® Technologies

Retrieved on: 
Wednesday, September 29, 2021

ClearRT is a novel, helical CT imaging solution designed to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively.

Key Points: 
  • ClearRT is a novel, helical CT imaging solution designed to produce exceptional diagnostic-like quality CT images, quickly and cost-effectively.
  • Unicancer is the only French hospital network 100 percent dedicated to the treatment of cancer.
  • "We made the decision to upgrade to the Radixact Systems to access its latest imaging and motion synchronization features ClearRT and Synchrony.
  • Unicancer is the only French hospital network dedicated 100% to the fight against cancer and the only national hospital federation dedicated to oncology.

Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch

Retrieved on: 
Thursday, April 22, 2021

The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.

Key Points: 
  • The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.
  • The ClearRT daily targeting images exceeded our expectations, and provided noticeably superior image quality compared to more traditional cone-beam CT available on conventional linear accelerators.
  • The imaging technology will now be available in Japan and the U.S. ClearRT imaging is expected to be accessible to EU customers following receipt of the CE Mark.
  • "\n*ClearRTHelical kVCT Imaging for the RadixactTreatment Delivery System is not available for sale in all markets.

Accuray Receives 510(k) FDA Clearance for ClearRT™ Helical kVCT Imaging for the Radixact® Treatment Delivery System

Retrieved on: 
Tuesday, January 5, 2021

Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the Spring of 2021.

Key Points: 
  • Accuray is planning commercial release of the ClearRT Helical kVCT Imaging for the Radixact System in the Spring of 2021.
  • The ClearRT imaging solution is seamlessly integrated into the Radixact System.
  • ClearRT leverages the same simple 5-step delivery workflow that makes the Radixact System easy to use, and easy to adopt.
  • *ClearRTHelical kVCT Imaging for the Radixact Treatment Delivery System is not available for sale in all markets.